FARRAGUT PARTNERS LLP

Lobbying for GENENTECH · Biotechnology

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Oct 20, 2025

Lobbying activity 2

Medicare/Medicaid

Issues regarding Medicare payment policies for Part B drugs. Issues related to the 340B Drug discount program. Drug Pricing Proposals. CMMI Guardrails. Issues related to drug pricing (IPI, Part B reforms). 21st century cures 2.0 legislation.

Health Issues

Issues related to the 340B Drug discount program. Drug Pricing Proposals. Issues related to drug pricing. 21st century cures 2.0 legislation.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.